Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic’s DES Program Sails Full Speed Ahead; Analysts Spy Iceberg

This article was originally published in The Gray Sheet

Executive Summary

The strength of Medtronic's drug-eluting stent pipeline renders acquisitions or partnerships unnecessary, the company asserts, citing confidence in U.S. commercialization of Endeavor by early 2006

You may also be interested in...



Medtronic’s DES Moment Of Truth: ACC Is Venue For Endeavor Results

Data from Medtronic's ENDEAVOR-II clinical trial, to be presented to the American College of Cardiology March 6, will reveal whether the company is on track to launch its drug-eluting stent in the U.S. by early 2006

Medtronic’s DES Moment Of Truth: ACC Is Venue For Endeavor Results

Data from Medtronic's ENDEAVOR-II clinical trial, to be presented to the American College of Cardiology March 6, will reveal whether the company is on track to launch its drug-eluting stent in the U.S. by early 2006

Medtronic Stent Patent Ruling Makes DES Vulnerable; Will Guidant Cut Deal?

Medtronic will appeal a Delaware federal court patent infringement ruling against its Driver and S7 coronary stents and challenge the validity of Guidant's Lau patent, the firm says

Related Content

UsernamePublicRestriction

Register

MT021011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel